Risk-based treatment approaches for neuroblastoma have been ongoing for decades.
However, the criteria used to define risk in various institutional and cooperative groups were …

Neuroblastoma is a developmental tumor of young children arising from the embryonic
sympathoadrenal lineage of the neural crest. Neuroblastoma is the primary cause of death …

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching
rules that supersede variability. Here, we define pan-cancer binary classes based on distinct …

Basal cell carcinoma (BCC) of the skin is the most common malignant neoplasm in humans.
BCC is primarily driven by the Sonic Hedgehog (Hh) pathway. However, its phenotypic …

In mammalian cells, the MYC oncoprotein binds to thousands of promoters,,,. During
mitogenic stimulation of primary lymphocytes, MYC promotes an increase in the expression …

Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors,
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by …

We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-
surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target …

The MYCN proto-oncogene is amplified in a number of advanced-stage human tumors, such
as neuroblastomas. Similar to other members of the MYC family of oncoproteins, MYCN …

The causes of pediatric cancers' distinctiveness compared to adult-onset tumors of the same
type are not completely clear and not fully explained by their genomes. In this study, we …

Neuroblastoma (NB) is a childhood cancer arising from sympatho-adrenal neural crest cells.
MYCN amplification is found in half of high-risk NB patients; however, no available therapies …